Wells Fargo upgraded 3M from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
| 11/13/2024 | $184.00 | Neutral → Buy | UBS |
| 10/22/2024 | Hold → Buy | Melius | |
| 9/6/2024 | $125.00 | Underweight | Morgan Stanley |
| 7/30/2024 | $145.00 | Hold → Buy | Argus |
| 7/29/2024 | $110.00 → $150.00 | Hold → Buy | Deutsche Bank |
| 6/13/2024 | $125.00 | Peer Perform → Outperform | Wolfe Research |
| 6/7/2024 | $105.00 → $120.00 | Neutral → Buy | BofA Securities |
4 - 3M CO (0000066740) (Issuer)
4 - 3M CO (0000066740) (Issuer)
4 - 3M CO (0000066740) (Issuer)
For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th
Wells Fargo upgraded 3M from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
UBS upgraded 3M from Neutral to Buy and set a new price target of $184.00
Melius upgraded 3M from Hold to Buy